Program
13-valent pneumococcal vaccine
Also written as “13-valent pneumococcal conjugate vaccine”, “13-valent Pneumococcal Conjugate Vaccine” and “13vPnC”.
Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Pneumonia · Influenza, Human · HIV Infections, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 570 open or running | phase 4since Aug 27, 2008 | Sep 19, 2005 | none ahead |
| CanSino Biologics | 31 open or running | phase 3since Apr 8, 2021 | Sep 18, 2019 | Feb 15, 2027phase 3 · NCT07017777 |
| Beijing Minhai Biotechnology | 10 open or running | phase 4since Jan 8, 2024 | Jan 8, 2024 | none ahead |
| Fosun Pharma | 11 open or running | phase 3since Feb 26, 2023 | Feb 26, 2023 | none ahead |
| Sinovac Biotech | 10 open or running | phase 1since Oct 13, 2021 | Oct 13, 2021 | none ahead |
| walvax-biotechnology-co-ltd | 10 open or running | phase 3since Mar 31, 2016 | Mar 31, 2016 | none ahead |
| wuhan-bravovax-co-ltd | 10 open or running | phase 1since Oct 24, 2022 | Oct 24, 2022 | none ahead |
Also a collaborator on its studies: Liaoning Chengda Biotechnology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Aug 25, 2006.
- May 22, 2018Phase 4 study in VaccinesPfizer · NCT03548337 · 301 enrolled · India
- May 25, 2018Phase 2 study in Pneumococcal InfectionsPfizer · NCT03550313 · 565 enrolled · United States
- Jun 20, 2018Phase 3 study in Pneumococcal InfectionsPfizer · NCT03571607 · 206 enrolled · Japan
- Dec 4, 2018Phase 4 study in VaccinesPfizer · NCT03777865 · 100 enrolled · India
- Sep 18, 2019CanSino Biologics’ first study: phase 1 study in Pneumococcal InfectionsNew to CanSino BiologicsCanSino Biologics · NCT04100772 · 237 enrolled · China
- Apr 8, 2021Phase 3 study in Pneumococcal InfectionsCanSino Biologics · NCT04841369 · 3,420 enrolled · China
- Oct 13, 2021Sinovac Biotech’s first study: phase 1 study in Pneumococcal InfectionsNew to Sinovac BiotechSinovac Biotech · NCT05092386 · 310 enrolled · China
- Mar 29, 2022No phase study in Immunogenicity, VaccinePfizer · NCT05372575 · 300 enrolled · China
- Apr 7, 2022Phase 4 study in Pneumococcal InfectionsPfizer · NCT05329259 · 200 enrolled · India
- Oct 24, 2022wuhan-bravovax-co-ltd’s first study: phase 1 study in Pneumococcal InfectionsNew to wuhan-bravovax-co-ltdwuhan-bravovax-co-ltd · NCT05602480 · 264 enrolled · China
- Feb 26, 2023Fosun Pharma’s first study: phase 3 study in Pneumococcal InfectionsNew to Fosun PharmaFosun Pharma · NCT05759520 · 1,800 enrolled · China
- Jan 8, 2024Beijing Minhai Biotechnology’s first study: phase 4 study in PneumoniaNew to Beijing Minhai BiotechnologyBeijing Minhai Biotechnology · NCT06210737 · 621 enrolled · China
- Jun 4, 2025Phase 3 study in Pneumococcal InfectionsCanSino Biologics · NCT07017777 · 600 enrolled · Thailand
- Jun 5, 2025Phase 1 study in Pneumococcal InfectionsPfizer · NCT07019909 · 400 enrolled · China
Ahead
- Feb 15, 2027Primary completion: phase 3 study in Pneumococcal InfectionsCanSino Biologics · NCT07017777
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A pneumococcal conjugate vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae, used in children and studied in immunocompromised patients for the prevention of pneumococcal disease”NCIt, by rule
Studies
The newest 60 of 65 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07019909Pneumococcal Infections · China | 1 | Completed | Pfizer | Jan 28, 2026 | 400 |
| NCT07017777Pneumococcal Infections · Thailand | 3 | Active, not recruiting | CanSino Biologics | Feb 15, 2027 | 600 |
| NCT06210737Pneumonia · China | 4 | Completed | Beijing Minhai Biotechnology | Nov 13, 2022 | 621 |
| NCT05759520Pneumococcal Infections · China | 3 | Active, not recruiting | Fosun Pharma | Jun 30, 2025 | 1,800 |
| NCT05602480Pneumococcal Infections · China | 1 | UNKNOWN | wuhan-bravovax-co-ltd | Jun 2024 | 264 |
| NCT05329259Pneumococcal Infections · India | 4 | Completed | Pfizer | Nov 30, 2022 | 200 |
| NCT05372575Immunogenicity, Vaccine · China | – | Completed | Pfizer | Dec 14, 2021 | 300 |
| NCT05092386Pneumococcal Infections · China | 1 | Completed | Sinovac Biotech | May 26, 2024 | 310 |
| NCT04841369Pneumococcal Infections · China | 3 | Completed | CanSino Biologics | Mar 30, 2022 | 3,420 |
| NCT04100772Pneumococcal Infections · China | 1 | Completed | CanSino Biologics | Jun 23, 2021 | 237 |
| NCT03777865Vaccines · India | 4 | Completed | Pfizer | Apr 17, 2019 | 100 |
| NCT03571607Pneumococcal Infections · Japan | 3 | Completed | Pfizer | Nov 16, 2018 | 206 |
| NCT03550313Pneumococcal Infections · United States | 2 | Terminated | Pfizer | Nov 5, 2020 | 565 |
| NCT03574389Pneumococcal Infections · China | 3 | Completed | Pfizer | Aug 23, 2021 | 936 |
| NCT03548337Vaccines · India | 4 | Completed | Pfizer | Dec 20, 2019 | 301 |
| NCT02736240Diseases Caused by Streptococcus Pneumoniae Serotypes | 3 | Completed | walvax-biotechnology-co-ltd | Dec 3, 2017 | 2,760 |
| NCT02124161Influenza, Human · United States | 4 | Completed | Pfizer | May 2015 | 882 |
| NCT02034877Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC · India | 4 | Completed | Pfizer | Jul 2015 | 1,200 |
| NCT01964716Pneumococcal Vaccines · Gambia | 3 | Completed | Pfizer | Sep 2014 | 500 |
| NCT01692886Pneumococcal Infections · China | 3 | Completed | Pfizer | Apr 2014 | 1,674 |
| NCT01646398Pneumococcal Vaccines · Japan | 3 | Completed | Pfizer | Oct 2012 | 764 |
| NCT01531322Pneumococcal Infections · China | 1 | Completed | Pfizer | Jan 2012 | 72 |
| NCT01392378Pneumococcal Vaccines · Poland | 4 | Completed | Pfizer | Jan 2013 | 908 |
| NCT01432262Pneumococcal Infections · Mexico | 3 | Completed | Pfizer | Dec 2011 | 324 |
| NCT01200368Healthy Subjects · Japan | 3 | Completed | Pfizer | Nov 30, 2011 | 551 |
| NCT01193335Premature Birth · Poland, Spain | 4 | Completed | Pfizer | Jan 2014 | 200 |
| NCT0102603813-valent Pneumococcal Vaccine · France | 3 | Completed | Pfizer | Nov 2010 | 263 |
| NCT00980655Vaccines, Pneumococcal Conjugate Vaccine · United States, Belgium, Canada and more | 3 | Completed | Pfizer | May 16, 2013 | 251 |
| NCT00963235HIV Infections · United States | 3 | Completed | Pfizer | May 2012 | 331 |
| NCT00962780HIV Infections · Romania, South Africa | 3 | Completed | Pfizer | Apr 2013 | 303 |
| NCT00918580Pneumococcal Conjugate Vaccine · United States, Egypt, France and more | 3 | Completed | Pfizer | Mar 2013 | 158 |
| NCT00853749Invasive Pneumococcal Disease · Iceland | 3 | Completed | Pfizer | Dec 16, 2009 | 89 |
| NCT00824850Pneumococcal Conjugate Vaccine · United States | 2 | Completed | Pfizer | Sep 2010 | 75 |
| NCT00824655Pneumococcal Vaccines · Sweden | 3 | Completed | Pfizer | Jun 2010 | 234 |
| NCT00761631Healthy Subjects · United States | 3 | Completed | Pfizer | Aug 10, 2010 | 1,200 |
| NCT00744263Pneumonia, Pneumococcal · Netherlands | 4 | Completed | Pfizer | Oct 2013 | 84,496 |
| NCT00743652Pneumococcal Infections · United States | 3 | Completed | Pfizer | Sep 2010 | 373 |
| NCT00708682Vaccines, Pneumococcal · Mexico | 3 | Completed | Pfizer | May 2010 | 225 |
| NCT00689351Disease · Korea, Republic of | 2 | Completed | Pfizer | Dec 2009 | 180 |
| NCT00688870Vaccines · Taiwan | 3 | Completed | Pfizer | Jan 13, 2010 | 168 |
| NCT00676091Vaccines, Pneumococcal Conjugate Vaccine · Brazil | 3 | Completed | Pfizer | Sep 2009 | 354 |
| NCT00574795Vaccines, Pneumococcal Conjugate Vaccine · Japan | 3 | Completed | Pfizer | Aug 2008 | 193 |
| NCT00574548Pneumococcal Vaccines · United States | 3 | Completed | Pfizer | Feb 2010 | 720 |
| NCT00562354Healthy · Japan | 3 | Completed | Pfizer | Dec 2007 | 271 |
| NCT00546572Pneumococcal Infections · United States, Sweden | 3 | Completed | Pfizer | Jul 2010 | 938 |
| NCT00521586Influenza, Human · United States | 3 | Completed | Pfizer | Dec 2013 | 1,116 |
| NCT00508742Pneumococcal Infections · Israel | 3 | Completed | Pfizer | Aug 2011 | 1,866 |
| NCT00500357Vaccines, Pneumococcal Conjugate Vaccine · South Africa | 3 | Completed | Pfizer | Jan 2010 | 105 |
| NCT00500266Pneumococcal Infections · United States, Germany, Sweden | 3 | Completed | Pfizer | Apr 2009 | 1,053 |
| NCT00492557Pneumococcal Infections | 3 | Completed | Pfizer | Feb 2008 | 1,185 |
| NCT00475033Vaccines, Pneumococcal Conjugate Vaccine · Canada | 3 | Completed | Pfizer | May 2009 | 603 |
| NCT00474539Vaccines, Pneumococcal · Spain | 3 | Completed | Pfizer | Mar 2009 | 449 |
| NCT00464945Pneumococcal Vaccines · Poland | 3 | Completed | Pfizer | Sep 2008 | 269 |
| NCT00452790Pneumococcal Infections · India | 3 | Completed | Pfizer | Oct 2009 | 708 |
| NCT00452452Pneumococcal Infections · Poland | 3 | Completed | Pfizer | Mar 2008 | 355 |
| NCT00444457Vaccines, Pneumococcal · United States | 3 | Completed | Pfizer | Jun 2009 | 1,712 |
| NCT00427895Pneumococcal Infections · United States | 3 | Completed | Pfizer | Aug 1, 2011 | 2,141 |
| NCT00384059Vaccines, Pneumococcal · United Kingdom | 3 | Completed | Pfizer | Oct 2008 | 286 |
| NCT00373958Vaccines, Pneumococcal · United States | 3 | Completed | Pfizer | Jun 2008 | 666 |
| NCT00368966Vaccines, Pneumococcal · Spain | 3 | Completed | Pfizer | Jul 2008 | 619 |
How it is read
Names in the registry
- “13-valent pneumococcal conjugate vaccine”, 23 entries
- “13-valent Pneumococcal Conjugate Vaccine”, 20 entries
- “13vPnC”, 9 entries
- “13-valent pneumococcal conjugate vaccine (13vPnC)”, 8 entries
- “PCV13”, 5 entries
Codes read as this program: PCV13I.
Conditions, from the studies’ own filings
- Pneumococcal Infections, 26 studies
- Pneumonia, Pneumococcal, 2 studies
- Pneumonia, 2 studies
- Influenza, Human, 2 studies
- HIV Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.